{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:15:19Z","timestamp":1766182519146,"version":"3.44.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010600","name":"Tampere University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010600","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.04.013","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T07:21:13Z","timestamp":1745997673000},"page":"999-1002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adjuvant Docetaxel Versus Surveillance in Intermediate- or High-risk Prostate Cancer After Radical Curative Radiotherapy: Final Survival Results from the SPCG-13 Trial"],"prefix":"10.1016","volume":"8","author":[{"given":"Pirkko-Liisa","family":"Kellokumpu-Lehtinen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Sofie","family":"Fransson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Marttila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilari","family":"Lehtinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppo","family":"Huttunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Thellenberg-Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.04.013_b0005","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2019.08.010","article-title":"Docetaxel versus surveillance after radical radiotherapy for high- or intermediate risk prostate cancer\u2014results from the prospective randomised, open-label phase III SPCG 13 trial","volume":"76","author":"Kellokumpu-Lehtinen","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.013_b0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.21873\/anticanres.15460","article-title":"Health-related quality of life in intermediate- or high-risk patients treated with radical external radiotherapy and adjuvant docetaxel for localized prostate cancer: a randomized, phase III SPCG-13 study","volume":"42","author":"Lehtonen","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.euo.2025.04.013_b0015","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.euf.2019.01.015","article-title":"Overview of systemic therapy augmenting management of high-risk localized prostate cancer","volume":"5","author":"Vicier","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.04.013_b0020","doi-asserted-by":"crossref","unstructured":"Fizazi K, Gillessen S, ESMO Guidelines Committee Clinical. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. eUpdate, March 21, 2023. https:\/\/www.esmo.org\/guidelines\/guidelines-by-topic\/esmo-clinical-practice-guidelines-genitourinary-cancers\/clinical-practice-guidelines-prostate-cancer\/eupdate-prostate-cancer-treatment-recommendations.","DOI":"10.1016\/j.annonc.2023.02.015"},{"year":"2024","series-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer","author":"Cornford","key":"10.1016\/j.euo.2025.04.013_b0025"},{"key":"10.1016\/j.euo.2025.04.013_b0030","unstructured":"American Urological Association. Clinically localized prostate cancer: AUA\/ASTRO guideline (2022). Linthicum, MD: AUA; 2022. https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/clinically-localized-prostate-cancer-aua\/astro-guideline-2022."},{"key":"10.1016\/j.euo.2025.04.013_b0035","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG Oncology RTOG 0521 trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.013_b0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","article-title":"Management of patients with advanced prostate cancer. Part I: intermediate-\/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the Advanced Prostate Cancer Consensus Conference","volume":"83","author":"Gillessen","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.013_b0045","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.21873\/anticanres.13728","article-title":"ANO7 rs77559646 germline variant associated with poor response to first-line docetaxel treatment in metastatic castration resistant prostate cancer (CRPC)","volume":"39","author":"Kaikkonen","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.euo.2025.04.013_b0050","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3390\/ijms24021052","article-title":"Transcripts of the prostate cancer-associated gene ANO7 are retained in the nuclei of prostatic epithelial cells","volume":"24","author":"Mets\u00e4l\u00e4","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"Suppl 2","key":"10.1016\/j.euo.2025.04.013_b0055","doi-asserted-by":"crossref","first-page":"S961","DOI":"10.1016\/j.annonc.2024.08.1677","article-title":"1596O \u2013 Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): an ancillary study of the STAMPEDE docetaxel trials","volume":"35","author":"Grist","year":"2024","journal-title":"Ann Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:25:50Z","timestamp":1758079550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125001117"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.013","relation":{},"ISSN":["2588-9311"],"issn-type":[{"type":"print","value":"2588-9311"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Docetaxel Versus Surveillance in Intermediate- or High-risk Prostate Cancer After Radical Curative Radiotherapy: Final Survival Results from the SPCG-13 Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}